Andy Batts
Long only, value, growth, momentum

Qiagen: Why I Prefer Waiting On The Sidelines

Netherlands-based Qiagen N.V. (NASDAQ:QGEN) is a leading global provider of sample and assay technologies. The company aims to accelerate growth in 2014 primarily by boosting the global adoption of its QIAsymphony platform and establishing the QuantiFeron-TB platform as the modern gold standard for latent tuberculosis control. In this article I will analyze whether these initiatives are enough for boosting shareholder value amid an extremely tough competitive environment.

QuantiFeron-TB Gold

Tuberculosis ("TB") is caused by the intracellular pathogen Mycobacterium tuberculosis ("MTB"). In 2011, Qiagen took over Australia's Cellestis, the company that developed QuantiFeron-TB, an FDA-approved interferon-gamma release assay ("IGRA") for the detection of tuberculosis infection. Qiagen has big plans for the QuantiFeron-TB Gold and its variant QuantiFeron-TB Gold In...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details